Management Credibility Analysis

Unavailable
Verified Management Score Unavailable
Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed
Verified Catalysts Unavailable
No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive
Not disclosed
Headquarters
68 XINQING ROAD, SUZHOU , JIANGSU, F4
Founded
Not disclosed

📈 Company Timeline

Major business events
Positive
Negative
Neutral
16 Sep 2025

Ascentage Pharma Group Internat securities registration filing

Ascentage Pharma Group Internat filed a registration or prospectus document concerning securities.

Capital Structure & Financial Position

Financial strength and liquidity analysis
Verified Capital Structure Unavailable
Balance-sheet, credit-rating, debt, and capital-activity data require sourced financial statement ingestion.

Peer Comparison - Health Care

Company Price Market Cap
LLY - Eli Lilly and Company $1,276.13
Yahoo Finance 		$1.20T
JNJ - Johnson & Johnson $256.74
Yahoo Finance 		$618.71B
ABBV - AbbVie Inc. $284.80
Yahoo Finance 		$503.28B
UNH - UnitedHealth Group Incorporated $418.43
Yahoo Finance 		$375.58B
MRK - Merck & Co., Inc. $148.55
Yahoo Finance 		$366.50B

📋 Corporate Actions

Recent and upcoming corporate events
Verified Corporate Actions Unavailable
Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis
Verified Financial Statements Unavailable
Verified financial statement data is not ingested for this stock yet.

Analyst Consensus

Buy
Target: $42.00
173.4% upside potential
📈
Strong Buy
Unavailable
👍
Buy
7
⏸️
Hold
0
📉
Sell
0
7 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved Targets range 33.00–48.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments
Verified Dividend Data Unavailable
Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable
Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity
21
May 2026
Zhai Yifan
Chief Medical Officer
Option exercise
Unavailable per share
188,321 shares
SEC Form 4
21
May 2026
Yang Dajun
Director, Chairman and CEO
Option exercise
Unavailable per share
188,321 shares
SEC Form 4

Top Shareholders

Point72 Asset Management, L.P.
13,841 shares
-13.795% change
6/30/2026
Morgan Stanley
919 shares
84.538% change
6/30/2026
Wells Fargo & Company/Mn
200 shares
New% change
6/30/2026
Eversource Wealth Advisors, Llc
24 shares
0% change
6/30/2026
Ubs Group Ag
15 shares
-87.903% change
6/30/2026
Blackrock, Inc.
6 shares
New% change
6/30/2026
Royal Bank Of Canada
6 shares
0% change
6/30/2026
Caitong International Asset Management Co., Ltd
1 shares
New% change
6/30/2026
Tower Research Capital Llc (Trc)
0 shares
Sold Out% change
6/30/2026
Xy Capital Ltd
0 shares
Sold Out% change
6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed · 1 day ago